Outcomes of retreatment with anti-PD-1 monotherapy after response to first course in patients with cutaneous melanoma.

Whitman, Eric D; Scherrer, Emilie; Ou, Wanmei; Krepler, Clemens

Whitman, Eric D; Scherrer, Emilie; Ou, Wanmei; Krepler, Clemens.

Affiliation

Whitman ED; Atlantic Melanoma Center, Atlantic Health System Cancer Care, 100 Madison Ave., Morristown, NJ 07960 USA.
Scherrer E; Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033 USA.
Ou W; Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033 USA.
Krepler C; Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033 USA.

Future Oncol ; 16(20): 1441-1453, 2020 Jul.

Article in En | MEDLINE | ID: mdl-32410465

Subject(s)

Antineoplastic Agents, Immunological/therapeutic use; Melanoma/drug therapy; Programmed Cell Death 1 Receptor/antagonists & inhibitors; Skin Neoplasms/drug therapy; Adult; Aged; Aged, 80 and over; Female; Humans; Immunotherapy; Male; Melanoma/pathology; Middle Aged; Retreatment; Retrospective Studies; Skin Neoplasms/pathology; Treatment Outcome

Key words

immunotherapy; outcomes research; real-world evidence; skin (melanoma)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Skin Neoplasms / Programmed Cell Death 1 Receptor / Antineoplastic Agents, Immunological / Melanoma Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Future Oncol Year: 2020 Type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google